Luteolin 4′-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo
Molecules · 2023
DOI: 10.3390/molecules28062609 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Riham A El-Shiekh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr el Aini St., Cairo 11562, Egypt. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Researchers Supporting Project number (RSP2023R497) at King Saud University, Riyadh, Saudi Arabia., King Saud University.
Abstract (Originalsprache)
Multidrug resistance (MDR) pathogens are usually associated with higher morbidity and mortality rates. Flavonoids are good candidates for the development of new potential antimicrobials. This research investigated whether luteolin 4′-neohesperidoside (L4N) has antibacterial and synergistic activities against four antibiotic-resistant pathogens: methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella pneumoniae, fosA-positive shiga toxin producing the Escherichia coli serogroup O111 (STEC O111), and Bacillus cereus. In vitro antimicrobial susceptibility testing revealed highly potent anti-MRSA (MIC of 106.66 ± 6.95 µg/mL), anti-K. pneumoniae (MIC of 53.33 ± 8.47 µg/mL) and anti-STEC O111 (MIC of 26.66 ± 5.23 µg/mL) activities. Significant synergistic combination was clearly noted in the case of gentamycin (GEN) against Gram-negative bacteria. In the case of B. cereus, the combination of vancomycin (VAN) with L4N could efficiently inhibit bacterial growth, despite the pathogen being VAN-resistant (MIC of 213.33 ± 7.9 µg/mL). In vivo evaluation of L4N showed significant decreases in K. pneumoniae and STEC shedding and colonization. Treatment could significantly diminish the levels of pro-inflammatory markers, tumor necrosis factor-alpha (TNF-α), and immunoglobulin (IgM). Additionally, the renal and pulmonary lesions were remarkably enhanced, with a significant decrease in the bacterial loads in the tissues. Finally, this study presents L4N as a potent substitute for traditional antibiotics with anti-STEC O111 and anti-K. pneumoniae potential, a finding which is reported here for the first time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacognosy, Faculty of Pharmacy, Cairo University, Kasr el Aini St., Cairo 11562, Egypt.
- School of Medical Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester M20 4GJ, UK.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62514, Egypt.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
- Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Microbiology and Immunology, Faculty of Pharmacy, Ahram Canadian University, Giza 12451, Egypt.
ORCID-Profile: Riham A El-Shiekh, Ibrahim A Naguib, Sarah I Bukhari, Rana Elshimy
Förderung
- Researchers Supporting Project number (RSP2023R497) at King Saud University, Riyadh, Saudi Arabia.
- King Saud University
Zitieren
APA
El-Shiekh, R. A., Elhemely, M. A., Naguib, I. A., Bukhari, S. I., & Elshimy, R. (2023). Luteolin 4′-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo. Molecules. https://doi.org/10.3390/molecules28062609
Vancouver
El-Shiekh RA, Elhemely MA, Naguib IA, Bukhari SI, Elshimy R. Luteolin 4′-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo. Molecules. 2023. doi:10.3390/molecules28062609
BibTeX
@article{ElShiekh2023,
author = {El-Shiekh, Riham A and Elhemely, Mai A and Naguib, Ibrahim A and Bukhari, Sarah I and Elshimy, Rana},
title = {Luteolin 4′-Neohesperidoside Inhibits Clinically Isolated Resistant Bacteria In Vitro and In Vivo},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28062609}
}
EUVIMED